It also does not expand your plans formulary or change your plans existing coverage rules
*In the STEP 1 trial, participants received semaglutide 2.4 mg once weekly via subcutaneous injection, the FDA-approved formulation later marketed under the brand name Wegovy for chronic weight management in adults with obesity or overweight and at least one weight-related condition
Research Areas of Interest All information below is strictly intended for laboratory, scientific, and in-vitro research discussion only
This three-entity structure - platform, independent clinicians, partner pharmacies - is standard across telehealth platforms and ensures appropriate separation between technology coordination, clinical decision-making, and medication dispensing
doi: 10.1172/jci72434 13 MulJDBeggDPBarreraJGLiBMatterEKD'AlessioDAet al
GLP-1 has been heavily marketed, and skepticism is healthy